



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: VCH-916

产品别名: VCH-916

生物活性:

Description	VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.																					
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : ≥ 39 mg/mL (78.36 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>2.0091 mL</td><td>10.0456 mL</td><td>20.0912 mL</td></tr><tr><td>5 mM</td><td>0.4018 mL</td><td>2.0091 mL</td><td>4.0182 mL</td></tr><tr><td>10 mM</td><td>0.2009 mL</td><td>1.0046 mL</td><td>2.0091 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p>					Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg	1 mM	2.0091 mL	10.0456 mL	20.0912 mL	5 mM	0.4018 mL	2.0091 mL	4.0182 mL	10 mM	0.2009 mL	1.0046 mL	2.0091 mL
Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg																		
	1 mM	2.0091 mL	10.0456 mL	20.0912 mL																		
5 mM	0.4018 mL	2.0091 mL	4.0182 mL																			
10 mM	0.2009 mL	1.0046 mL	2.0091 mL																			
References	<p>[1]. Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92</p> <p>[2]. Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161.</p> <p>[3]. Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703</p> <p>[4]. Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164</p> <p>[5]. Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection</p>																					